Sugi Predict

Sugi Predict / Compounds / SCHEMBL12515368

SCHEMBL12515368

SCHEMBL12515368

COc1ccc(NC(=O)[C@H](CCCCN)NC(=O)c2cc(NC(=O)[C@H](CCCCN)NC(=O)c3cc(NC(=O)[C@H](CCCCN)NC(=O)c4cc(N)ccc4OC)ccc3OC)ccc2OC)cc1C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MMP2 P08253 2/20 0.41
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ERAP2 Q6P179 5/20 0.39
▸ LNPEP Q9UIQ6 3/20 0.39
▸ KCNB1 Q14721 3/20 0.39
▸ ERAP1 Q9NZ08 2/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ PDF Q9HBH1 1/20 0.37
▸ HDAC4 P56524 1/20 0.37
▸ MEF2D Q14814 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19445715 0.99 KLKB1 (0.41) KLKB1TSHRMMP2KMT2AMEN1
SCHEMBL21371597 0.99 KLKB1 (0.41) KLKB1TSHRMMP2KMT2AMEN1
SCHEMBL12515365 0.91 ALDH1A1 (0.43) KLKB1TSHRMMP2KMT2AMEN1
SCHEMBL12766955 0.91 MMP2 (0.43) KLKB1TSHRMMP2KMT2AMEN1
SCHEMBL12767238 0.91 ALDH1A1 (0.43) KLKB1TSHRMMP2KMT2AMEN1
SCHEMBL10262850 0.91 KLKB1 (0.42) KLKB1TSHRMMP2KMT2AMEN1
SCHEMBL16907359 0.91 KLKB1 (0.42) KLKB1TSHRMMP2KMT2AMEN1
SCHEMBL10260677 0.90 KLKB1 (0.41) KLKB1TSHRMMP2KMT2AMEN1
Delparantag SCHEMBL10267622 0.90 ERAP2 (0.47) KLKB1TSHRMMP2ERAP2LNPEP
SCHEMBL10261735 0.90 KLKB1 (0.41) KLKB1TSHRMMP2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10603294-B2 Compounds for use in treatment of mucositis INNOVATION PHARMACEUTICALS INC. (US) 2020-03-31 — — US disclosed
US-20190282521-A1 Compounds For Use In Treatment Of Mucositis POLYMEDIX, INC. 2019-09-19 — — US disclosed
US-10206894-B2 Compounds for use in treatment of mucositis INNOVATION PHARMACEUTICALS INC. (US) 2019-02-19 — — US disclosed
US-20180064664-A1 Compounds For Use In Treatment of Mucositis POLYMEDIX, INC. 2018-03-08 — — US disclosed
US-9795575-B2 Compounds for use in treatment of mucositis INNOVATION PHARMACEUTICALS INC. (US) 2017-10-24 — — US disclosed
EP-2709619-B1 COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS CELLCEUTIX CORP (US) 2017-10-11 — — EP disclosed
US-20170224640-A1 Compounds For Use In Treatment Of Mucositis INNOVATION PHARMACEUTICALS INC. 2017-08-10 — — US disclosed
US-20170224640-A1 Compounds For Use In Treatment Of Mucositis INNOVATION PHARMACEUTICALS INC. 2017-08-10 — — US disclosed
US-9457027-B2 Compounds for use in treatment of mucostis CELLCEUTIX CORPORATION (US) 2016-10-04 — — US disclosed
US-20160213668-A1 Compounds for use in Treatment of Mucostis INNOVATION PHARMACEUTICALS INC. 2016-07-28 — — US disclosed
US-9155738-B2 Compounds for use in treatment of mucostitis CELLCEUTIX CORPORATION (US) 2015-10-13 — — US disclosed
US-20140364364-A1 COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS INNOVATION PHARMACEUTICALS INC. 2014-12-11 — — US disclosed
US-8802683-B2 Compounds for use in treatment of mucositis CELLCEUTIX CORPORATION (US) 2014-08-12 — — US disclosed
US-20120295922-A1 Compounds For Use In Treatment Of Mucositis POLYMEDIX, INC. (US) 2012-11-22 — — US disclosed
WO-2012158672-A2 COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS POLYMEDIX, INC. (US) 2012-11-22 — — WO disclosed
US-20110178104-A1 Anti-Heparin Compounds POLYMEDIX INC. (US) 2011-07-21 — — US disclosed
WO-2011084970-A1 ANTI-HEPARIN COMPOUNDS POLYMEDIX INC. (US) 2011-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170224640-A1 Compounds For Use In Treatment Of Mucositis MUC1, FUT6, MMP8 KLKB1 1324/4885TSHR 4275/4885MMP2 367/4885
US-10603294-B2 Compounds for use in treatment of mucositis MUC1, FUT6, MMP8 KLKB1 1324/4885TSHR 4275/4885MMP2 367/4885
US-20140364364-A1 COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS MUC1, FUT6, MMP8 KLKB1 1324/4885TSHR 4275/4885MMP2 367/4885
US-20120295922-A1 Compounds For Use In Treatment Of Mucositis MUC1, FUT6, MMP8 KLKB1 1324/4885TSHR 4275/4885MMP2 367/4885
US-10206894-B2 Compounds for use in treatment of mucositis MUC1, FUT6, SI KLKB1 1370/4885TSHR 4769/4885MMP2 595/4885
US-20110178104-A1 Anti-Heparin Compounds SERPINC1, CFH, SERPINH1 KLKB1 302/4885TSHR 2112/4885MMP2 174/4885
US-20190282521-A1 Compounds For Use In Treatment Of Mucositis MUC1, FUT6, MMP8 KLKB1 1324/4885TSHR 4275/4885MMP2 367/4885
US-20180064664-A1 Compounds For Use In Treatment of Mucositis MUC1, FUT6, SI KLKB1 1370/4885TSHR 4769/4885MMP2 595/4885
US-20160213668-A1 Compounds for use in Treatment of Mucostis MUC1, SOST, ALG1 KLKB1 1372/4885TSHR 3166/4885MMP2 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback